Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Nuclear Medicine and Molecular Imaging
Published in: Nuclear Medicine and Molecular Imaging 3/2012

01-09-2012 | Original Article

Value of Surveillance 18F-FDG PET/CT in Colorectal Cancer: Comparison with Conventional Imaging Studies

Authors: Eun Kyoung Choi, Ie Ryung Yoo, Hye Lim Park, Hyun Su Choi, Eun Ji Han, Sung Hoon Kim, Soo Kyo Chung, Joo Hyun O

Published in: Nuclear Medicine and Molecular Imaging | Issue 3/2012

Login to get access

Abstract

Purpose

To assess the value of PET/CT for detecting local or distant recurrence in patients who undergo surgery for colorectal cancer (CRC) and to compare the accuracy of PET/CT to that of conventional imaging studies (CIS).

Methods

Tumor surveillance PET/CT scans done between March 2005 and December 2009 of disease-free patients after surgery with or without adjuvant chemotherapy for CRC were retrospectively studied. CIS (serial enhanced CT from lung base to pelvis and plain chest radiograph) were performed within 1 month of PET/CT. We excluded patients with distant metastasis on initial staging, a known recurrent tumor, and a lack of follow-up imaging. The final diagnosis was based on at least 6 months of follow-up with colonoscopy, biopsy, and serial imaging studies in combination with carcinoembryonic antigen levels.

Results

A total of 262 PET/CT scans of 245 patients were included. Local and distant recurrences were detected in 27 cases (10.3%). On case-based analysis, the overall sensitivity, specificity, and accuracy were 100, 97.0, and 97.3% for PET/CT and 85.1, 97.0, and 95.8% for CIS, respectively. On lesion-based analysis, PET/CT detected more lesions compared to CIS in local recurrence and lung metastasis. PET/CT and CIS detected the same number of lesions in abdominal lymph nodes, hepatic metastasis, and peritoneal carcinomatosis. PET/CT detected two more metachronous tumors than did CIS in the lung and thyroid gland.

Conclusion

PET/CT detected more recurrences in patients who underwent surgery for CRC than did CIS and had the additional advantage of evaluating the entire body during a single scan.
Literature
1.
Jung KW, Park S, Kong HJ, Won YJ, Lee JY, Park EC, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008. Cancer Res Treat. 2011;43(1):1–11.PubMedCrossRef
2.
Benson 3rd AB. The hope for today—the promise for tomorrow: will oncologists meet the challenge? J Clin Oncol. 2007;25(16):2156–8.PubMedCrossRef
3.
Desch CE, Benson 3rd AB, Somerfield MR, Flynn PJ, Krause C, Loprinzi CL, et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2005;23(33):8512–9.PubMedCrossRef
4.
Ariyan CE, Salem RR. Evolution in the treatment of metastatic colorectal carcinoma of the liver. World J Gastroenterol. 2006;12(20):3253–8.PubMed
5.
Fernandes LC, Kim SB, Saad SS, Matos D. Value of carcinoembryonic antigen and cytokeratins for the detection of recurrent disease following curative resection of colorectal cancer. World J Gastroenterol. 2006;12(24):3891–4.PubMed
6.
Ruers TJ, Langenhoff BS, Neeleman N, Jager GJ, Strijk S, Wobbes T, et al. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol. 2002;20(2):388–95.PubMedCrossRef
7.
Flamen P, Hoekstra OS, Homans F, Van Cutsem E, Maes A, Stroobants S, et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer. 2001;37(7):862–9.PubMedCrossRef
8.
Flanagan FL, Dehdashti F, Ogunbiyi OA, Kodner IJ, Siegel BA. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg. 1998;227(3):319–23.PubMedCrossRef
9.
Huebner RH, Park KC, Shepherd JE, Schwimmer J, Czernin J, Phelps ME, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med. 2000;41(7):1177–89.PubMed
10.
Metser U, You J, McSweeney S, Freeman M, Hendler A. Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen. AJR Am J Roentgenol. 2010;194(3):766–71.PubMedCrossRef
11.
Yoon H, Lee J, Kim Y, Kim S. FDG-PET/CT is superior to enhanced CT in detecting recurrent subcentimeter lesions in the abdominopelvic cavity in colorectal cancer. Nucl Med Mol Imaging. 2011;45(2):132–8.CrossRef
12.
Wood EH. The National Comprehensive Cancer Network (NCCN). J Med Libr Assoc. 2004;92(3):382–3.
13.
Sobhani I, Tiret E, Lebtahi R, Aparicio T, Itti E, Montravers F, et al. Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer. Br J Cancer. 2008;98(5):875–80.PubMedCrossRef
14.
Takeuchi O, Saito N, Koda K, Sarashina H, Nakajima N. Clinical assessment of positron emission tomography for the diagnosis of local recurrence in colorectal cancer. Br J Surg. 1999;86(7):932–7.PubMedCrossRef
15.
Valk PE, Abella-Columna E, Haseman MK, Pounds TR, Tesar RD, Myers RW, et al. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg. 1999;134(5):503–11, discussion 11–3.PubMedCrossRef
16.
Even-Sapir E, Parag Y, Lerman H, Gutman M, Levine C, Rabau M, et al. Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology. 2004;232(3):815–22.PubMedCrossRef
17.
Votrubova J, Belohlavek O, Jaruskova M, Oliverius M, Lohynska R, Trskova K, et al. The role of FDG-PET/CT in the detection of recurrent colorectal cancer. Eur J Nucl Med Mol Imaging. 2006;33(7):779–84.PubMedCrossRef
18.
Shamim SA, Kumar R, Halanaik D, Shandal V, Reddy RM, Bal CS, et al. Role of FDG-PET/CT in detection of recurrent disease in colorectal cancer. Nucl Med Commun. 2010;31(6):590–6.
19.
Kyoto Y, Momose M, Kondo C, Itabashi M, Kameoka S, Kusakabe K. Ability of 18F-FDG PET/CT to diagnose recurrent colorectal cancer in patients with elevated CEA concentrations. Ann Nucl Med. 2010;24(5):395–401.
20.
Lee JH, Park SG, Jee KN, Park DG, Namgung H, Song IH. Performance of FDG PET/CT in postoperative colorectal cancer patients with a suspected recurrence and a normal CEA level. Nucl Med Commun. 2010;31(6):576–82.
21.
Liu Y. Clinical significance of diffusely increased splenic uptake on FDG-PET. Nucl Med Commun. 2009;30(10):763–9.PubMedCrossRef
22.
Tomas MB, Tronco GG, Karayalcin G, Palestro CJ. 22. FDG uptake in infectious mononucleosis. Clin Positron Imaging. 2000;3(4):176.PubMedCrossRef
23.
Lustberg MB, Aras O, Meisenberg BR. FDG PET/CT findings in acute adult mononucleosis mimicking malignant lymphoma. Eur J Haematol. 2008;81(2):154–6.PubMedCrossRef
24.
Kernstine KH, Grannis FW, Rotter AJ. Is there a role for PET in the evaluation of subcentimeter pulmonary nodules? Semin Thorac Cardiovasc Surg. 2005;17(2):110–4.PubMedCrossRef
25.
JH O, Yoo Ie R, Kim SH, Sohn HS, Chung SK. Clinical significance of small pulmonary nodules with little or no 18F-FDG uptake on PET/CT images of patients with nonthoracic malignancies. J Nucl Med. 2007;48(1):15–21.
26.
Kalff V, Hicks RJ, Ware RE, Hogg A, Binns D, McKenzie AF. The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med. 2002;43(4):492–9.PubMed
27.
Scott AM, Gunawardana DH, Kelley B, Stuckey JG, Byrne AJ, Ramshaw JE, et al. PET changes management and improves prognostic stratification in patients with recurrent colorectal cancer: results of a multicenter prospective study. J Nucl Med. 2008;49(9):1451–7.PubMedCrossRef
28.
Meta J, Seltzer M, Schiepers C, Silverman DH, Ariannejad M, Gambhir SS, et al. Impact of 18F-FDG PET on managing patients with colorectal cancer: the referring physician’s perspective. J Nucl Med. 2001;42(4):586–90.PubMed
Metadata
Title
Value of Surveillance 18F-FDG PET/CT in Colorectal Cancer: Comparison with Conventional Imaging Studies
Authors
Eun Kyoung Choi
Ie Ryung Yoo
Hye Lim Park
Hyun Su Choi
Eun Ji Han
Sung Hoon Kim
Soo Kyo Chung
Joo Hyun O
Publication date
01-09-2012
Publisher
Springer-Verlag
Published in
Nuclear Medicine and Molecular Imaging / Issue 3/2012
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-012-0145-9

Other articles of this Issue 3/2012

Nuclear Medicine and Molecular Imaging 3/2012 Go to the issue

Original Article

Imaging Myocardial Ischemia and Reperfusion Injury via Cy5.5-Annexin V

Original Article

Dual-time-point FDG PET/CT: Is It Useful for Lymph Node Staging in Patients with Non-Small-Cell Lung Cancer?

Interesting Image

Endometrial Cancer with Cervical Extension Mimicking Dual Concordant Endometrial and Cervical Malignancy by F-18 FDG PET and MRI

Original Article

Prognostic value of SUVmax measured by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography in Patients with Pancreatic Cancer

Original Article

Implications of Three-Phase Bone Scintigraphy for the Diagnosis of Bisphosphonate-Related Osteonecrosis of the Jaw

Interesting Image

Rituximab-Induced Lung Injury in a Case of NHL: Diagnosis and Follow-Up on FDG PET/CT